Growing pains and workload are taxing the US Food and Drug Administration’s cell and gene therapy staff as they prepare for increased attention from a growing sector.
A new name and reorganization may offer some relief.
The group will be called the Office of Therapeutic Products, but needs more people to handle its increasing workload.

Growing pains and workload are taxing the US Food and Drug Administration’s cell and gene therapy staff as they prepare for increased attention from a growing sector.
A new name and reorganization may offer some relief.
In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.
Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.
Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.